Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Total Liabilities: 2017-2025

Historic Total Liabilities for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $123.9 million.

  • Crinetics Pharmaceuticals' Total Liabilities rose 18.65% to $123.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.9 million, marking a year-over-year increase of 18.65%. This contributed to the annual value of $109.8 million for FY2024, which is 14.07% up from last year.
  • As of Q3 2025, Crinetics Pharmaceuticals' Total Liabilities stood at $123.9 million, which was up 4.93% from $118.0 million recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Total Liabilities peaked at $123.9 million during Q3 2025, and registered a low of $14.1 million during Q1 2021.
  • In the last 3 years, Crinetics Pharmaceuticals' Total Liabilities had a median value of $104.4 million in 2024 and averaged $94.0 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first declined by 8.91% in 2021, then surged by 206.48% in 2024.
  • Quarterly analysis of 5 years shows Crinetics Pharmaceuticals' Total Liabilities stood at $19.1 million in 2021, then surged by 87.97% to $35.8 million in 2022, then soared by 168.49% to $96.2 million in 2023, then rose by 14.07% to $109.8 million in 2024, then climbed by 18.65% to $123.9 million in 2025.
  • Its Total Liabilities stands at $123.9 million for Q3 2025, versus $118.0 million for Q2 2025 and $107.3 million for Q1 2025.